What is the real per-recipient economic value?

Varies by active challenge and development phase. Award minimum: not published. Dilution/equity: none.

Which jurisdictions and applicants are eligible?

Eligibility and product scope are solicitation-specific. Historical official FAQs describe open solicitations and permit current or past RADx companies to apply, but founders must verify the current health challenge before treating the program as open.

A diagnostic technology matched to the active challenge; A credible rapid validation and regulatory path; A team able to execute compressed milestone-based development

What burden or follow-on should I expect?

NIH Standard Award Terms and Conditions plus negotiated work packages, milestones, clinical/regulatory evidence and program reviews. Progression and additional work packages are milestone-dependent; not an automatic recurring award.

NIH RADx Tech

Varies by active challenge and development phase · National Institutes of Health

NIH RADx Tech is a grant programme from National Institutes of Health for U.S. and eligible international teams or companies developing diagnostic technologies for an active RADx Tech challenge Current status: unknown; Challenge-specific solicitations rather than a universal rolling grant; no current general submission deadline was shown on the checked program page. Award economics: Varies by active challenge and development phase; dilution/equity: none.

Tier 1 · ranked #9governmentunited-stateshealthdiagnostics

Apply Official site Open in the live directory

Key facts

Funder	National Institutes of Health
Amount	Varies by active challenge and development phase
Decision time	The RADx innovation funnel uses staged technical, clinical, regulatory and commercialization work packages; timing depends on the live solicitation.
Eligibility	Eligibility and product scope are solicitation-specific. Historical official FAQs describe open solicitations and permit current or past RADx companies to apply, but founders must verify the current health challenge before treating the program as open.
Restrictions	NIH Standard Award Terms and Conditions plus negotiated work packages, milestones, clinical/regulatory evidence and program reviews. Dilution/equity: none.
Status	unknown

Always confirm on the official page before applying — dates and terms change.

Application process

Find a live RADx health-challenge solicitation
Submit the solicitation-specific proposal rather than a standard R01/R21
Technical and program review
Negotiate staged work packages and milestones
Advance through validation and regulatory/commercialization support if milestones are met

Background

National Institutes of Health operates NIH RADx Tech. The official-source pass separates the currently actionable opportunity from historical cohorts and separates per-recipient value from headline program envelopes. The official program page links a dashboard, authorized-test list and outcomes from the COVID-19 program.

How the application really works

Find a live RADx health-challenge solicitation → Submit the solicitation-specific proposal rather than a standard R01/R21 → Technical and program review → Negotiate staged work packages and milestones → Advance through validation and regulatory/commercialization support if milestones are met

Tips

Demonstrate: A diagnostic technology matched to the active challenge
Demonstrate: A credible rapid validation and regulatory path
Demonstrate: A team able to execute compressed milestone-based development

Watch out for

Current status is unknown; do not use an archived form.
Dilution/equity treatment: none.
NIH Standard Award Terms and Conditions plus negotiated work packages, milestones, clinical/regulatory evidence and program reviews.

Track record

The official program page links a dashboard, authorized-test list and outcomes from the COVID-19 program.

No current cross-solicitation acceptance rate is published.

Frequently asked questions

Is this opportunity actionable now?: unknown. Challenge-specific solicitations rather than a universal rolling grant; no current general submission deadline was shown on the checked program page.
What is the real per-recipient economic value?: Varies by active challenge and development phase. Award minimum: not published. Dilution/equity: none.
Which jurisdictions and applicants are eligible?: Eligibility and product scope are solicitation-specific. Historical official FAQs describe open solicitations and permit current or past RADx companies to apply, but founders must verify the current health challenge before treating the program as open.
How does selection work?: Find a live RADx health-challenge solicitation; Submit the solicitation-specific proposal rather than a standard R01/R21; Technical and program review; Negotiate staged work packages and milestones; Advance through validation and regulatory/commercialization support if milestones are met. The RADx innovation funnel uses staged technical, clinical, regulatory and commercialization work packages; timing depends on the live solicitation.
What appears to win?: A diagnostic technology matched to the active challenge; A credible rapid validation and regulatory path; A team able to execute compressed milestone-based development
What burden or follow-on should I expect?: NIH Standard Award Terms and Conditions plus negotiated work packages, milestones, clinical/regulatory evidence and program reviews. Progression and additional work packages are milestone-dependent; not an automatic recurring award.

Sources

www.nibib.nih.gov/programs/radx-tech-program — Official current program description, outcomes and contacts (checked 2026-08-10)
www.nibib.nih.gov/covid-19/radx-initiative-covid-19-testing/FAQs — Official eligibility, scope and NIH award-term examples (checked 2026-08-10)